Ignyta, Inc.

Pfizer Corporation

Bristol-Myers Squibb Compnay

Qed Therapeutics, Inc.

Gang Li

Zachary Dolph Hornby

Haichun Huang

Brigitte Devaux

Peter Brams

Steven Lee Bender

Haibin Chen

Kristopher Toy

Mark Yamanaka

Dawn M Tanamachi

Lan Yang

Garrett M Brodeur

Gerald Fries Casperson

Michael Aidan North

Dana Dan Hu-Lowe

Xin Jiang

Jianying Wang

Tim Sproul

David Wesley Anderson

Radhika Iyer

Grant Wickman

Ge Wei

Susan Arangio

Jonathan Ee-ren Lim

Michael Monteith

Carl Dambkowski

Riccardo Panicucci

Craig Berman

Daniel Mulreany

Michael Howland

Tim W Sproul

Provided herein are methods of treating advanced or metastatic cholangiocarcinoma in a patient by administering to the patient infigratinib or a pharmaceutically acceptable salt thereof, wherein the patient has progression of the cholangiocarcinoma after previous administration of another therapy.

Methods of treating cholangiocarcinoma

Described herein are combinations comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROS1, TrkA, TrkB, or TrkC activity, or a combination thereof, and methods of using such combinations in the treatment of patients having cancer.

Combinations for the treatment of cancer

Disclosed are methods of treating neuroblastoma in a cancer patient by administration of a Trk inhibitor in combination with one more chemotherapeutic agents. Also disclosed are pharmaceutical compositions comprising a Trk inhibitor and one or more chemotherapeutic agents.

Combinations for the treatment of neuroblastoma

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin &#x3b1;5&#x3b2;1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-&#x3b1;5&#x3b2;1 antibodies or antigen binding portions thereof described herein.

Alpha5-beta1 antibodies and their uses

Alpha 5-beta 1 antibodies and their uses

Growing community of inventors

San Diego, CA, United States of America

Gang Li